File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients

TitleHigh-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients
Authors
KeywordsNon-small-cell lung carcinoma
Prognosis
Rad51
Tissue microarray
Issue Date2005
PublisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/bjc
Citation
British Journal Of Cancer, 2005, v. 93 n. 1, p. 137-143 How to Cite?
AbstractHigh-level expression of Rad51, a key factor in homologous recombination, has been observed in a variety of human malignancies. This study was aimed to evaluate Rad51 expression to serve as prognostic marker in non-small-cell lung cancer (NSCLC). A total of 383 non-small-cell lung tumours were analysed immunohistochemically on NSCLC tissue microarrays. High-level Rad51 expression was observed in 29.4% (100 out of 340) of cases. Patients whose tumours displayed high-level Rad51 expression showed a significantly shorter median survival time of 19 vs 68 months (P < 0.0001, log-rank test). Similarly T status, N status, M status, clinical stage and histological tumour grade were significant prognostic markers in univariate Cox survival analysis. Importantly, Rad51 expression (P < 0.0001) together with tumour differentiation (P < 0.009), clinical stage (P = 0.004) and N status (P = 0.0001) proved to be independent prognostic parameters in multivariate analysis. Rad51 expression predicted the outcome of squamous cell cancer as well as adenocarcinoma of the lung. Our results suggest that Rad51 expression provides additional prognostic information for surgically treated NSCLC patients. We hypothesise that the decreased survival of NSCLC patients with high-level expression of Rad51 is related to an enhanced propensity of tumour cells for survival, antiapoptosis and chemo-/radioresistance. © 2005 Cancer Research UK. All Rights Reserved.
Persistent Identifierhttp://hdl.handle.net/10722/71988
ISSN
2023 Impact Factor: 6.4
2023 SCImago Journal Rankings: 3.000
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorQiao, GBen_HK
dc.contributor.authorWu, YLen_HK
dc.contributor.authorYang, XNen_HK
dc.contributor.authorZhong, WZen_HK
dc.contributor.authorXie, Den_HK
dc.contributor.authorGuan, XYen_HK
dc.contributor.authorFischer, Den_HK
dc.contributor.authorKolberg, HCen_HK
dc.contributor.authorKruger, Sen_HK
dc.contributor.authorStuerzbecher, HWen_HK
dc.date.accessioned2010-09-06T06:37:13Z-
dc.date.available2010-09-06T06:37:13Z-
dc.date.issued2005en_HK
dc.identifier.citationBritish Journal Of Cancer, 2005, v. 93 n. 1, p. 137-143en_HK
dc.identifier.issn0007-0920en_HK
dc.identifier.urihttp://hdl.handle.net/10722/71988-
dc.description.abstractHigh-level expression of Rad51, a key factor in homologous recombination, has been observed in a variety of human malignancies. This study was aimed to evaluate Rad51 expression to serve as prognostic marker in non-small-cell lung cancer (NSCLC). A total of 383 non-small-cell lung tumours were analysed immunohistochemically on NSCLC tissue microarrays. High-level Rad51 expression was observed in 29.4% (100 out of 340) of cases. Patients whose tumours displayed high-level Rad51 expression showed a significantly shorter median survival time of 19 vs 68 months (P < 0.0001, log-rank test). Similarly T status, N status, M status, clinical stage and histological tumour grade were significant prognostic markers in univariate Cox survival analysis. Importantly, Rad51 expression (P < 0.0001) together with tumour differentiation (P < 0.009), clinical stage (P = 0.004) and N status (P = 0.0001) proved to be independent prognostic parameters in multivariate analysis. Rad51 expression predicted the outcome of squamous cell cancer as well as adenocarcinoma of the lung. Our results suggest that Rad51 expression provides additional prognostic information for surgically treated NSCLC patients. We hypothesise that the decreased survival of NSCLC patients with high-level expression of Rad51 is related to an enhanced propensity of tumour cells for survival, antiapoptosis and chemo-/radioresistance. © 2005 Cancer Research UK. All Rights Reserved.en_HK
dc.languageengen_HK
dc.publisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/bjcen_HK
dc.relation.ispartofBritish Journal of Canceren_HK
dc.subjectNon-small-cell lung carcinoma-
dc.subjectPrognosis-
dc.subjectRad51-
dc.subjectTissue microarray-
dc.subject.meshCarcinoma, Non-Small-Cell Lung - metabolism - pathologyen_HK
dc.subject.meshDNA-Binding Proteins - metabolismen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHumansen_HK
dc.subject.meshImmunohistochemistryen_HK
dc.subject.meshLung Neoplasms - metabolism - pathologyen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshOligonucleotide Array Sequence Analysisen_HK
dc.subject.meshPrognosisen_HK
dc.subject.meshRad51 Recombinaseen_HK
dc.subject.meshSurvival Analysisen_HK
dc.titleHigh-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patientsen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0007-0920&volume=93&issue=1&spage=137&epage=143&date=2005&atitle=High-level+expression+of+Rad51+is+an+independent+prognostic+marker+of+survival+in+non-small-cell+lung+cancer+patientsen_HK
dc.identifier.emailGuan, XY:xyguan@hkucc.hku.hken_HK
dc.identifier.authorityGuan, XY=rp00454en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1038/sj.bjc.6602665en_HK
dc.identifier.pmid15956972-
dc.identifier.scopuseid_2-s2.0-23044437224en_HK
dc.identifier.hkuros100388en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-23044437224&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume93en_HK
dc.identifier.issue1en_HK
dc.identifier.spage137en_HK
dc.identifier.epage143en_HK
dc.identifier.isiWOS:000230265000019-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridQiao, GB=8318743700en_HK
dc.identifier.scopusauthoridWu, YL=8974511600en_HK
dc.identifier.scopusauthoridYang, XN=8318743600en_HK
dc.identifier.scopusauthoridZhong, WZ=16065101400en_HK
dc.identifier.scopusauthoridXie, D=35070710200en_HK
dc.identifier.scopusauthoridGuan, XY=7201463221en_HK
dc.identifier.scopusauthoridFischer, D=9133488000en_HK
dc.identifier.scopusauthoridKolberg, HC=6603834538en_HK
dc.identifier.scopusauthoridKruger, S=35360386000en_HK
dc.identifier.scopusauthoridStuerzbecher, HW=8537181600en_HK
dc.identifier.citeulike227992-
dc.identifier.issnl0007-0920-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats